- **Name / Position**

  Tseng, Chih-Hua Professor

- **Office Address**：

  School of Pharmacy

  College of Pharmacy

  Kaohsiung Medical University

  100, Shih-Chuan 1st Rd. Kaohsiung, Taiwan, 807

- **E-mail**：chihhua@kmu.edu.tw
- **Tel**：886-7-3121101 ext. 2163
- **Fax**：886-7-3210683
- **Teaching Courses**

  Medicinal Chemistry

  Cosmetic and Synthesis Chemistry

  Ethics in Pharmacy

  Special Topics on Medicinal Chemistry
  Special Topics on Drug Synthesis and Design

- **The Highest Education Degree**

  Ph.D. in Graduate Institute of Pharmaceutical Sciences, Kaohsiung Medical University

- **Personal Experiences**

  Pharmacist, Chest Hospital Department of Health Executive Yuan, Tainan

  Adjunct Lecturer, Department of Cosmetic Applications & Management, Tung Fang Institute of Technology

  Post doctoral research fellow, Kaohsiung Medical University

- **Research Area**

  1. Synthesis and characterization of medicinally active heterocyclic compounds.

  2. Development of new synthetic methodologies for the synthesis of natural product.

  3. Pharmacological studies of newly synthesized heterocyclic compounds.

- **Select Publications**

1 Tang, K. W.; Hsu, C. Y.; Aljuffali, I. A.; Alalaiwe, A.; Lai, W. N.; Gu, P. Y.; **Tseng, C. H.***; Fang, J. Y.* Skin delivery of synthetic benzoyl pterostilbenes suppresses atopic dermatitis-like inflammation through the inhibition of keratinocyte and macrophage activation. *Biomed. Pharmacother.* **2024**, *170*, 116073. (SCI, IF_{2023} = 6.9, 15/354 = 4.23%)

2 Cheng, K. W.[#]; **Tseng, C. H.** [#]; Chen, I. J.; Huang, B. C.; Liu, H. J.; Ho, K. W.; Lin, W. W.; Chuang, C. H.; Huang, M. Y.; Leu, Y. L.; Roffler, S. R. Wang, J. W.; Chen, Y. L.*; Chenh, T. L.* Inhibition of gut microbial β-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis. *Pharmacol. Res.* **2022**, *177*, 106115. (SCI, IF_{2021} = 10.334, 16/276 = 5.80%)

3 Kant, R. [#]; Yang, M. H. [#]; **Tseng, C. H.** [#]; Yen, C. H.; Li, W. Y.; Tyan, Y. C.; Chen, M.; Tzeng, C. C.; Chen, W. C.; You, K.; Wang, W. C.; Chen, Y. L.*; Chen, Y. A.* Discovery of an orally efficacious MYC inhibitor for liver cancer using a GNMT-based high-throughput screening system and structure-activity relationship analysis. *J. Med. Chem.* **2021**, *64*, 8992-9009. (SCI, IF_{2020} = 7.446, 3/63 = 4.76%)

4 Tang, K. W.; Hsu, W. L.; Chen, C.R.; Tsai, M. H.; Yen, C. J.; **Tseng, C. H.*** Discovery of triazolyl thalidomide derivatives as anti-fibrosis agents. *New J. Chem.* **2021**, *45,* 3589-3599. (SCI, IF_{2020} = 3.591, 75/178 = 42.13%)

5 Tang, K. W.; Lin, Z. C.; Wang, P. W.; Alalaiwe, A.; **Tseng, C. H.***; Fang, J. Y.* Facile skin targeting of a thalidomide analog containing benzyl chloride moiety alleviates experimental psoriasis via the suppression of MAPK/NF-κB/AP-1 phosphorylation in keratinocytes. *J. Dermatol. Sci.* **2020**, *99,* 90-99. (SCI, IF_{2019} = 3.681, 12/68 = 17.65%)

6 Fang, J. Y.; Tang, K. W.; Yang, S. H.; Alalaiwe, A.; Yang, Y. C.; **Tseng C. H.***; Yang, S. C.* Synthetic Naphthofuranquinone Derivatives Are Effective in Eliminating Drug-Resistant *Candida albicans* in Hyphal, Biofilm, and Intracellular Forms: An Application for Skin-Infection Treatment. *Front. Microbiol.* **2020**, *11*, 2053. (SCI, IF_{2019} = 4.235, 34/135 = 25.19%)

7 Kant, R. [#]; Yang, M. H. [#]; **Tseng, C. H.** [#]; Yen, C. H.; Li, W. Y.; Tyan, Y. C.; Chen, M.; Tzeng, C. C.; Chen, W. C.; You, K.; Wang, W. C.; Chen, Y. L.*; Chen, Y. A.* Discovery of an orally efficacious MYC inhibitor for liver cancer using a GNMT-based high-throughput screening system and structure-activity relationship analysis. *J. Med. Chem.* **2021**, *64*, 8992-9009. (SCI, IF_{2020} = 7.446, 3/63 = 4.76%)

8 Cheng, K. W. [#]; **Tseng, C. H.**[#]; Tzeng, C. C.; Leu, Y. L.; Cheng, T. C.; Wang, J. Y.; Chang J. M.; Lu, Y. C.; Cheng, C. M.; Chen, I. J.; Cheng, Y. A.; Chen Y. L.*; Cheng, T. L.* Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo. *Pharmacol. Res.* **2019**, *139*, 41-49. (SCI, IF_{2018} = 5.574, 18/267 = 6.74%)

9 **Tseng, C. H.***; Lin, C. K.; Chen, Y. L.; Tseng, C. K.; Lee, J. Y.; Lee, J. C.* Discovery of naphtho[1,2-d]oxazole derivatives as potential anti-HCV agents through inducing heme oxygenase-1 expression. *Eur. J. Med. Chem.* **2018,** Jan; *143,* 970-982. (SCI, IF_{2016} = 4.519, 4/60 = 6.67%)

10 Lee, J. C.; Tseng, C. K.; Lin, C. K.; **Tseng C. H.*** Discovery of novel diarylpyrazolylquinoline derivatives as potent anti-dengue virus agents. *Eur. J. Med. Chem.* **2017,** Dec; *141,* 282-292. (SCI, IF_{2016} = 4.519, 4/60 = 6.67%)

11 Cheng, K. W. [#]; **Tseng, C. H.**[#]; Yang, C. N.; Tzeng, C. C.; Cheng, T. C.; Leu, Y. L.; Chuang, Y. C.; Wang, J. W.; Lu, Y.C.; Chen Y. L.*; Cheng, T. L.* Specific inhibition of bacterial β-glucuronidase by pyrazolo[4,3-c]quinoline derivatives via a pH-dependent manner to suppress chemotherapy-induced intestinal toxicity. *J. Med. Chem.* **2017,** Nov; *60*, 9222-9238. (SCI, IF_{2016} = 6.259, 3/60 = 5%)

12 Yang, S. C.; Yen, F. L.; Wang, P. W.; Aljuffali, I. A.; Weng, Y. H.; **Tseng, C. H.***; Fang, J. Y.* Naphtho[1,2-b]furan-4,5-dione is a potent anti-MRSA agent against planktonic, biofilm, and intracellular bacteria. *Future Microbiol.* **2017** Sep; *12*, 1059-1073. (SCI, IF_{2016} = 3.374, 39/124 = 31.45%)